niraparib

Niraparib (MK-4827) is a PARP inhibitor that selectively targets PARP1 and PARP2 (IC50=3.8 2.1 nM), exhibiting antitumor activity, inhibiting DNA damage repair, and inducing apoptosis.

Niraparib tosylate (MK-4827 (tosylate))(with IC50 of 3.8 nM 2.1 nM) is a selective PARP1 PARP2 inhibitor.

Niraparib hydrochloride (MK-4827 hydrochloride) is an inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity. By inhibiting PARP activity, niraparib hydrochloride increases DNA strand breaks, leading to genomic instability and apoptosis. The PARP family of proteins detects and repairs single-strand DNA breaks via the base-excision repair (BER) pathway.

Niraparib metabolite M1 (Niraparib carboxylic acid metabolite M1) is the carboxylic acid metabolite of Niraparib. Niraparib is a novel poly (ADP-ribose) polymerase (PARP) inhibitor used in cancer research.

Niraparib, also know as MK-4827, is an inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity. MK4827 inhibits PARP activity, enhancing the accumulation of DNA strand breaks and promoting genomic instability and apoptosis. The PARP family of proteins detect and repair single strand DNA breaks by the base-excision repair (BER) pathway.

Niraparib metabolite M1 HCl is the active metabolite of Niraparib, as a novel targeted ADP ribose polymerase (PARP) inhibitor, it can competitively inhibit PARP1 and PARP2 to block the DNA repair mechanism of tumor cells and thus effectively inhibit the growth and proliferation, which is commonly used in the study of ovarian cancer, fallopian tube cancer and primary peritoneal cancer, and is commonly used in the study of ovarian, fallopian tube and primary peritoneal cancers.

Niraparib R-enantiomer (MK 4827 R-enantiomer) is an inhibitor of PARP1(IC50 of 2.4 nM).

MK-4827 Racemate (Niraparib Racemate) is a selective PARP1 and PARP2 inhibitor with IC50s of 3.8 nM and 2.1 nM, respectively, over 330-fold selectivity for PARP3, V-PARP and Tank1.